7754 Share Price Performance
Recent 7754 News & Updates
No updates
AnnJi Pharmaceutical Co., Ltd. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.77
- Gross Margin
- 9.22%
- Net Profit Margin
- -367.02%
- Debt/Equity Ratio
- 0%
AnnJi Pharmaceutical Co., Ltd. Competitors
About 7754
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy, a neurodegenerative disease; AJ202 for androgenetic alopecia; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. AnnJi Pharmaceutical Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
Taiwanese Market Performance
- 7 Days: 0.6%
- 3 Months: 12.7%
- 1 Year: 2.4%
- Year to Date: 2.3%
Over the last 7 days, the market has remained flat, although notably the Energy sector gained 9.2% in that time. Similarly, the market is flat for the past 12 months. As for the next few years, earnings are expected to grow by 13% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading